Trials / Terminated
TerminatedNCT00765466
A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- McGill University · Academic / Other
- Sex
- All
- Age
- 19 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, Phase II, multi-center study designed to evaluate the effect of AVR118 when administered to patients with systemic symptoms related to recurrent or metastatic cancers who may or may not be undergoing anti-cancer treatment. During the initial, induction treatment phase of the study, AVR118, 4.0 mL, will be given subcutaneously each day for 28 days. Patients who respond to the trial period dosing will be eligible to continue on AVR118 if they and their physicians believe it would be beneficial, and if no safety concerns are raised.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVR118 | daily doses of 4.0 mL AVR118 subcutaneously |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2008-10-03
- Last updated
- 2019-03-14
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00765466. Inclusion in this directory is not an endorsement.